252 related articles for article (PubMed ID: 12196859)
1. Metformin and polycystic ovary syndrome: a literature review.
Awartani KA; Cheung AP
J Obstet Gynaecol Can; 2002 May; 24(5):393-401. PubMed ID: 12196859
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
4. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction.
Stadtmauer LA; Wong BC; Oehninger S
Hum Reprod; 2002 Dec; 17(12):3016-26. PubMed ID: 12456596
[TBL] [Abstract][Full Text] [Related]
5. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.
Morin-Papunen LC; Koivunen RM; Ruokonen A; Martikainen HK
Fertil Steril; 1998 Apr; 69(4):691-6. PubMed ID: 9548159
[TBL] [Abstract][Full Text] [Related]
6. Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.
Berker B; Emral R; Demirel C; Corapcioglu D; Unlu C; Kose K
Gynecol Endocrinol; 2004 Sep; 19(3):125-33. PubMed ID: 15697073
[TBL] [Abstract][Full Text] [Related]
7. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
Kolodziejczyk B; Duleba AJ; Spaczynski RZ; Pawelczyk L
Fertil Steril; 2000 Jun; 73(6):1149-54. PubMed ID: 10856473
[TBL] [Abstract][Full Text] [Related]
8. [Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
Laboureau-Soares Barbosa S; Rodien P; Rohmer V
Ann Endocrinol (Paris); 2002 Feb; 63(1):31-5. PubMed ID: 11937980
[TBL] [Abstract][Full Text] [Related]
9. Metformin therapy in women with polycystic ovary syndrome.
Aruna J; Mittal S; Kumar S; Misra R; Dadhwal V; Vimala N
Int J Gynaecol Obstet; 2004 Dec; 87(3):237-41. PubMed ID: 15548396
[TBL] [Abstract][Full Text] [Related]
10. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
[TBL] [Abstract][Full Text] [Related]
11. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Chou KH; von Eye Corleta H; Capp E; Spritzer PM
Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
[TBL] [Abstract][Full Text] [Related]
12. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance, polycystic ovary syndrome and metformin.
Pugeat M; Ducluzeau PH
Drugs; 1999; 58 Suppl 1():41-6; discussion 75-82. PubMed ID: 10576524
[TBL] [Abstract][Full Text] [Related]
14. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Costello M; Shrestha B; Eden J; Sjoblom P; Johnson N
Cochrane Database Syst Rev; 2007 Jan; (1):CD005552. PubMed ID: 17253562
[TBL] [Abstract][Full Text] [Related]
15. The treatment of polycystic ovary syndrome.
Ajossa S; Guerriero S; Paoletti AM; Orrù M; Melis GB
Minerva Ginecol; 2004 Feb; 56(1):15-26. PubMed ID: 14973407
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and metabolic characteristics in polycystic ovary syndrome.
Glintborg D
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
[TBL] [Abstract][Full Text] [Related]
17. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Gambineri A; Pelusi C; Genghini S; Morselli-Labate AM; Cacciari M; Pagotto U; Pasquali R
Clin Endocrinol (Oxf); 2004 Feb; 60(2):241-9. PubMed ID: 14725687
[TBL] [Abstract][Full Text] [Related]
18. Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group.
Norman RJ; Kidson WJ; Cuneo RC; Zacharin MR
Med J Aust; 2001 Jun; 174(11):580-3. PubMed ID: 11453331
[TBL] [Abstract][Full Text] [Related]
19. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome.
Khorram O; Helliwell JP; Katz S; Bonpane CM; Jaramillo L
Fertil Steril; 2006 May; 85(5):1448-51. PubMed ID: 16579997
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
Elkind-Hirsch KE
Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
